常山药业(300255) - 2018 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2018 was CNY 328,413,253.38, representing a 28.36% increase compared to CNY 255,855,738.51 in the same period last year[8] - Net profit attributable to shareholders was CNY 45,379,800.76, up 5.55% from CNY 42,993,977.10 year-on-year[8] - Operating income for the reporting period was 328.41 million yuan, an increase of 28.36% year-on-year, with net profit attributable to shareholders rising by 5.55% to 45.38 million yuan[24] - Net profit for Q1 2018 reached CNY 46,875,449.32, compared to CNY 44,659,205.68 in Q1 2017, representing a growth of 4.9%[48] - The total comprehensive income attributable to the parent company was CNY 45,379,800.76, compared to CNY 42,993,977.10 in the previous year, reflecting a growth of 5.5%[51] Cash Flow - Net cash flow from operating activities was negative CNY 83,550,267.88, a decline of 15.04% compared to negative CNY 72,628,498.82 in the previous year[8] - The company reported a net cash outflow from operating activities of CNY -83,550,267.88, worsening from CNY -72,628,498.82 in the same quarter last year[55] - Cash and cash equivalents decreased from 797,654,244.43 RMB to 769,886,605.64 RMB during the reporting period[39] - Cash outflow from investing activities totaled $32,787,614.55, slightly down from $35,073,750.91[59] - Total cash outflow for operating activities reached $480,754,595.54, compared to $310,679,779.45 previously, marking a 55% increase[59] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,653,116,209.27, an increase of 3.49% from CNY 3,530,047,343.32 at the end of the previous year[8] - The company's total assets as of the end of Q1 2018 were CNY 3,596,254,150.56, an increase from CNY 3,467,406,055.61 at the beginning of the year[44] - Total liabilities increased to CNY 1,170,849,543.97 from CNY 1,094,656,127.34, marking a rise of 6.9%[44] - The total equity attributable to shareholders of the parent company was CNY 2,414,831,089.08, up from CNY 2,369,451,288.32, indicating a growth of 1.9%[42] Shareholder Information - The major shareholder, Gao Shuhua, holds 36.41% of the shares, totaling 340,394,728 shares, with 255,296,046 shares pledged[15] - The company has a total of 10,648,126 shares held by Ji Shengli, accounting for 1.14% of the total shares[15] - The total number of shares held by the top 10 unrestricted shareholders is 117,403,020 shares, representing 12.56% of the total shares[15] - The company has released 34,880,682 restricted shares from Gao Shuhua, reducing his restricted shares to 255,296,046[18] - The total number of restricted shares at the end of the period is 325,325,292 shares, with 288,783,982 shares released during the period[19] Expenses - Total operating costs for Q1 2018 were CNY 272,893,924.41, up from CNY 204,771,164.70, reflecting a year-over-year increase of 33.3%[48] - Sales expenses increased by 51.08% year-on-year, mainly due to higher marketing expenses[22] - The company reported an increase in sales expenses to CNY 123,264,571.55 from CNY 81,589,540.76, reflecting a rise of 51.1%[48] - Research and development expenses increased by 45.02% year-on-year, reflecting the company's increased investment in R&D[22] - The financial expenses for the quarter were CNY 11,052,855.79, an increase from CNY 3,553,936.68 in Q1 2017[51] Market and Competition - The company is facing risks from increasing competition in the heparin raw material market, which could impact its existing advantages[10] - The company plans to enhance its R&D capabilities and product offerings to mitigate risks from market competition[10] - The company is also addressing procurement cost risks by monitoring heparin raw material prices and establishing its own supply base[11] - The company plans to optimize its procurement and sales system, ensuring stable supply channels and enhancing market share[26] Other Information - The company received government subsidies amounting to CNY 1,570,878.07 during the reporting period[9] - The company established a wholly-owned subsidiary with a registered capital of 50 million yuan to enhance the production of heparin crude products[25] - The company did not engage in any repurchase agreements during the reporting period[16] - The company has not experienced any significant changes in project feasibility or non-compliance with external guarantees during the reporting period[34][35] - There were no adjustments to the profit distribution policy during the reporting period[33]